Oclaiz

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of a Boeing C-17 Globemaster III during maintenance, illustrating Boeing’s $166.8 million landing gear spares contract modification and the growing strategic importance of military airlift sustainment.

Why Boeing’s $166.8 m C-17 spares win could matter more than it looks for BA stock

Why selective immune homeostasis is the bigger story behind CUE-401

Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt

Representative image of a large precious metals mining operation, illustrating the Fresnillo plc share price surge as investors weigh whether the FTSE 100 miner’s 2026 guidance cut is a temporary pause in the silver and gold bull run.

Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?

Camurus resubmits Oclaiz for FDA review as subcutaneous acromegaly therapy eyes June 2026 decision

Camurus's Oclaiz is back in FDA review for acromegaly. Find out what the June 2026 decision could mean for U.S. access and endocrine market disruption.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

January 12, 2026